EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 141 filers reported holding EAGLE PHARMACEUTICALS INC in Q3 2016. The put-call ratio across all filers is 0.34 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,202 | -97.3% | 203 | -96.6% | 0.00% | – |
| Q2 2023 | $117,359 | -44.2% | 6,037 | -18.6% | 0.00% | – |
| Q1 2023 | $210,278 | -78.7% | 7,412 | -78.1% | 0.00% | -100.0% |
| Q4 2022 | $987,331 | -36.0% | 33,778 | -42.2% | 0.00% | 0.0% |
| Q3 2022 | $1,543,000 | +27.3% | 58,391 | +114.1% | 0.00% | 0.0% |
| Q2 2022 | $1,212,000 | +52.1% | 27,278 | +69.4% | 0.00% | – |
| Q1 2022 | $797,000 | -56.3% | 16,106 | -55.0% | 0.00% | -100.0% |
| Q4 2021 | $1,823,000 | +53.7% | 35,796 | +68.4% | 0.00% | 0.0% |
| Q3 2021 | $1,186,000 | -34.6% | 21,257 | -49.8% | 0.00% | 0.0% |
| Q2 2021 | $1,813,000 | +1.7% | 42,362 | -0.8% | 0.00% | 0.0% |
| Q1 2021 | $1,782,000 | +424.1% | 42,699 | +484.5% | 0.00% | – |
| Q4 2020 | $340,000 | +9.0% | 7,305 | -0.5% | 0.00% | – |
| Q3 2020 | $312,000 | -62.2% | 7,344 | -57.4% | 0.00% | -100.0% |
| Q2 2020 | $826,000 | +35.4% | 17,223 | +29.8% | 0.00% | 0.0% |
| Q1 2020 | $610,000 | +33.5% | 13,268 | +74.4% | 0.00% | – |
| Q4 2019 | $457,000 | -57.2% | 7,609 | -59.7% | 0.00% | -100.0% |
| Q3 2019 | $1,067,000 | +275.7% | 18,864 | +269.7% | 0.00% | – |
| Q2 2019 | $284,000 | -5.6% | 5,102 | -14.2% | 0.00% | – |
| Q1 2019 | $301,000 | -93.3% | 5,949 | -94.7% | 0.00% | -100.0% |
| Q4 2018 | $4,512,000 | +36.2% | 111,978 | +134.3% | 0.01% | +66.7% |
| Q3 2018 | $3,313,000 | +17.1% | 47,785 | +27.8% | 0.00% | 0.0% |
| Q2 2018 | $2,828,000 | +14.6% | 37,380 | -20.2% | 0.00% | +50.0% |
| Q1 2018 | $2,468,000 | +2.6% | 46,833 | +4.0% | 0.00% | 0.0% |
| Q4 2017 | $2,405,000 | -17.7% | 45,027 | -8.1% | 0.00% | 0.0% |
| Q3 2017 | $2,924,000 | +10.2% | 49,022 | +45.7% | 0.00% | 0.0% |
| Q2 2017 | $2,654,000 | +64.7% | 33,642 | +73.2% | 0.00% | +100.0% |
| Q1 2017 | $1,611,000 | -72.7% | 19,424 | -73.8% | 0.00% | -80.0% |
| Q4 2016 | $5,893,000 | +954.2% | 74,279 | +831.3% | 0.01% | +400.0% |
| Q3 2016 | $559,000 | +4558.3% | 7,976 | +2515.1% | 0.00% | – |
| Q2 2016 | $12,000 | -95.1% | 305 | -95.0% | 0.00% | – |
| Q1 2016 | $246,000 | +161.7% | 6,064 | +472.1% | 0.00% | – |
| Q4 2015 | $94,000 | -78.6% | 1,060 | -82.1% | 0.00% | – |
| Q3 2015 | $439,000 | +4777.8% | 5,926 | +5238.7% | 0.00% | – |
| Q2 2015 | $9,000 | – | 111 | +692.9% | 0.00% | – |
| Q3 2014 | $0 | – | 14 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 3,652,284 | $302,920,000 | 91.10% |
| Hudson Executive Capital LP | 1,901,200 | $157,686,000 | 21.62% |
| JW Asset Management, LLC | 525,755 | $43,606,000 | 9.08% |
| Cormorant Asset Management, LP | 200,000 | $16,588,000 | 2.41% |
| Park West Asset Management LLC | 488,128 | $40,485,000 | 2.36% |
| Opaleye Management Inc. | 50,000 | $4,147,000 | 2.06% |
| Ranger Investment Management | 283,954 | $23,551,000 | 1.71% |
| Pier Capital, LLC | 74,732 | $6,198,000 | 1.06% |
| Bellevue Group AG | 67,700 | $5,615,000 | 0.75% |
| Orbimed Advisors | 671,000 | $55,653,000 | 0.63% |